Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children

Clinical and Diagnostic Laboratory Immunology

Volumn 11, Issue 5, 2004, Pages 913-918

  Rager Zisman, Bracha ^a   Bazarsky, Elina ^a   Skibin, Agneta ^a   Tam, Guy ^a   Chamney, Shlomo ^a   Belmaker, Ilana ^a   Shai, Iris ^a   Kordysh, Ella ^b   Griffin, Diane E ^c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; IMMUNOGLOBULIN G; MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MMRII; NEUTRALIZING ANTIBODY; PHYTOHEMAGGLUTININ; TETANUS TOXOID;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY TITER; ARAB; ARTICLE; CELL PROLIFERATION; CHILD; CYTOLYSIS; DRUG EFFECT; DRUG RESPONSE; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC DIFFERENCE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; ISRAEL; JEW; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MEASLES; MEASLES VACCINATION; MUMPS; NATURAL KILLER CELL; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RUBELLA; SEROCONVERSION; SIDE EFFECT;

ANTIBODIES, VIRAL; ANTIBODY FORMATION; ARABS; HUMANS; IMMUNOGLOBULIN G; INFANT; ISRAEL; JEWS; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; MEASLES-MUMPS-RUBELLA VACCINE;

EID: 4644281711     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.11.5.913-918.2004     Document Type: Article

References (32)

1. Anonymous. 2003. Update: global measles control and mortality reduction-worldwide, 1991-2001. Morb. Mortal. Wkly. Rep. 52:471-475.
2. Black, F. L., and S. R. Sheridan. 1967. Blood leukocyte response to live measles vaccine. Am. J. Dis. Child. 113:301-304.
3. Ceyhan, M., G. Kanra, G. Erdem, and B. Kanra. 2001. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age. Vaccine 19:4473-4478.
4. Dilraj, A., F. T. Cutts, J. F. de Castro, J. G. Wheeler, D. Brown, C. Roth, H. M. Coovadia, and J. V. Bennett. 2000. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet 355:798-803.
5. Forsey, T., A. Heath, and P. Minor. 1991. The 1st International Standard for anti-measles serum. Biologicals 19:237-241.
6. Gans, H. A., A. M. Arvin, J. Galinus, L. Logan, R. DeHovitz, and Y. Maldonado. 1998. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 280:527-532.
7. Griffin, D. E. 1995. Immune responses during measles virus infection. Curr. Top. Microbiol. Immunol. 191:117-134.
8. Griffin, D. E., S. J. Cooper, R. L. Hirsch, R. T. Johnson, I. Lindo de Soriano, S. Roedenbeck, and A. Vaisberg. 1985. Changes in plasma IgE levels during complicated and uncomplicated measles virus infections. J. Allergy Clin. Immunol. 76:206-213.
9. Griffin, D. E., and B. J. Ward. 1993. Differential CD4 T cell activation in measles. J. Infect. Dis. 168:275-281.
10. Griffin, D. E., B. J. Ward, E. Jauregui, R. T. Johnson, and A. Vaisberg. 1989. Immune activation during measles. N. Engl. J. Med. 320:1667-1672.
11. Griffin, D. E., B. J. Ward, E. Jauregui, R. T. Johnson, and A. Vaisberg. 1990. Natural killer cell activity during measles. Clin. Exp. Immunol. 81:218-224.
12. Holt, E. A., L. H. Moulton, G. K. Siberry, and N. A. Halsey. 1993. Differential mortality by measles vaccine titer and sex. J. Infect. Dis. 168:1087-1096.
13. Hussey, G. D., E. A. Goddard, J. Hughes, J. J. Ryon, M. Kerran, E. Carelse, P. M. Strebel, L. E. Markowitz, J. Moodie, P. Barren, Z. Latief, R. Sayed, D. Beatty, and D. E. Griffin. 1996. The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune responses in infants. J. Infect. Dis. 173:1320-1326.
14. Jacobson, R. M., G. A. Poland, R. A. Vierkant, V. S. Pankratz, D. J. Schaid, S. J. Jacobsen, J. St Sauver, and S. B. Moore. 2003. The association of class I HLA alleles and antibody levels after a single dose of measles vaccine. Hum. Immunol. 64:103-109.
15. Johnson, R. T., D. E. Griffin, R. L. Hirsch, J. S. Wolinsky, S. Roedenbeck, I. Lindo de Soriano, and A. Vaisberg. 1984. Measles encephalomyelitis-clinical and immunologic studies. N. Engl. J. Med. 310:137-141.
16. Kiepeila, P., H. M. Coovadia, and P. Coward. 1987. T helper cell defect related to severity in measles. Scand. J. Infect. Dis. 19:185-192.
17. Klinge, J., S. Lugauer, K. Korn, U. Heininger, and K. Stehr. 2000. Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age. Vaccine 18:3134-3140.
18. Knudsen, K. M., P. Aaby, H. Whittle, M. Rowe, B. Samb, F. Simondon, J. Sterne, and P. Fine. 1996. Child mortality following standard, medium or high titre measles immunization in West Africa. Int. J. Epidemiol. 25:665-673.
19. Munyer, T. P., R. J. Mangi, T. Dolan, and F. S. Kantor. 1975. Depressed lymphocyte function after measles-mumps-rubella vaccination. J. Infect. Dis. 132:75-78.
20. Muscat, M., S. Glismann, and H. Bang. 2003. Measles in Europe in 2001-2002. Eur. Surveill. 8:123-129.
21. Pabst, H. F., D. W. Spady, M. M. Carson, H. T. Stelfox, J. A. Beeler, and M. P. Krezolek. 1997. Kinetics of immunologic responses after primary MMR vaccination. Vaccine 15:10-14.
22. Poland, G. A., R. M. Jacobson, S. A. Colbourne, A. M. Thampy, J. J. Lipsky, P. C. Wollan, P. Roberts, and S. J. Jacobsen. 1999. Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects. Vaccine 17:1525-1531.
23. Poland, G. A., I. G. Ovsyannikova, R. M. Jacobson, R. A. Vierkant, S. J. Jacobsen, V. S. Pankratz, and D. J. Schaid. 2001. Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine 20:430-438.
24. Rager-Zisman, B., E. Bazarsky, A. Skibin, S. Chamney, I. Belmaker, I. Shai, E. Kordysh, and D. E. Griffin. 2003. The effect of measles-mumps-rubella (MMR) immunization on the immune responses of previously immunized primary school children. Vaccine 21:2580-2588.
25. Rager-Zisman, B., and T. Merigan. 1973. A useful quantitative semimicro-method for viral plaque assay. Proc. Soc. Exp. Biol. Med. 142:1174-1179.
26. Ryon, J., W. Moss, M. Monze, and D. E. Griffin. 2002. Functional and phenotypic changes in circulating lymphocytes from hospitalized Zambian children with measles. Clin. Diagn. Lab. Immunol. 9:994-1003.
27. Schnorr, J. J., F. T. Cutts, J. G. Wheeler, S. M. Akramuzzaman, M. S. Alam, T. Azim, S. Schneider-Schaulies, and V. ter Meulen. 2001. Immune modulation after measles vaccination of 6-9 months old Bangladeshi infants. Vaccine 19:1503-1510.
28. Shiozawa, S., N. Yoshikawa, K. Iijima, and K. Negishi. 1988. A sensitive radioimmunoassay for circulating alpha-interferon in the plasma of healthy children and patients with measles virus infection. Clin. Exp. Immunol. 73:366-369.
29. Smedman, L., A. Joki, A. P. daSilva, M. Troye-Blomberg, B. Aronsson, and P. Perlmann. 1994. Immunosuppression after measles vaccination. Acta Paediatr. 83:164-168.
30. St Sauver, J. L., I. G. Ovsyannikova, R. M. Jacobson, S. J. Jacobsen, R. A. Vierkant, D. J. Schaid, V. S. Pankratz, E. M. Green, and G. A. Poland. 2002. Associations between human leukocyte antigen homozygosity and antibody levels to measles vaccine. J. Infect. Dis. 185:1545-1549.
31. Tan, P. L., R. M. Jacobson, G. A. Poland, S. J. Jacobsen, and V. S. Pankratz. 2001. Twin studies of immunogenicity-determining the genetic contribution to vaccine failure. Vaccine 19:2434-2439.
32. Ward, B. J., N. Boulianne, S. Ratnam, M.-C. Guiot, M. Couillard, and G. DeSerres. 1995. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J. Infect. Dis. 172:1591-1595.